EntryPoint Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

EntryPoint Capital’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,993	Closed	-$201K	–	837
2025 Q3	$201K	Buy	+1,993	New	+$185K	0.08%	555
2024 Q1	–	Sell	-317	Closed	-$14.6K	–	1711
2023 Q4	$14.6K	Buy	+317	New	+$10K	0.01%	1109

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EntryPoint Capital's RYTM Position: Q4 2025 in Review

EntryPoint Capital sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2025, closing a stake of 1,993 shares — an estimated $201K sold.

EntryPoint Capital first reported a position in RYTM in Q4 2023 and held it in 2 quarters. The position peaked at $201K in Q3 2025. 279 funds tracked by Wall St. Rank hold RYTM as of Q4 2025.

EntryPoint Capital reported no remaining Rhythm Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
EntryPoint Capital sold 1,993 Rhythm Pharmaceuticals shares in Q4 2025, an estimated $201K.
EntryPoint Capital first reported a position in Rhythm Pharmaceuticals in Q4 2023 and held it in 2 quarters.
EntryPoint Capital's Rhythm Pharmaceuticals position peaked at $201K in Q3 2025.
279 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2025.

Based on EntryPoint Capital's 13F filing for Q4 2025, filed 12 Feb 2026.